Syngene International on Wednesday informed the bourses that it has entered into a pact with US-based Zumutor Biologics for biotherapeutic antibody discovery services.
As part of the non-exclusive partnering agreement, Syngene will have access to Zumutor’s proprietary naive human phage/yeast display library.
Under the agreement, Syngene will screen target antigens against Zumutor’s proprietary human antibody libraries to identify and characterise novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programmes for its partners.
This partnership will expand Syngene’s portfolio of therapeutic antibody discovery platforms. Shares of Syngene edged down 0.53 per cent at ₹605.5 on the NSE.